Bispecific Antibody Expands Reach to Follicular Lymphoma
The FDA approved the immunotherapy epcoritamab-bysp for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA)...
Progress Against Cancer
The FDA approved the immunotherapy epcoritamab-bysp for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA)...
The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other...
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients...
The immunotherapy durvalumab may be used with chemotherapy to treat certain endometrial cancers. The U.S. Food and Drug Administration...
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. ...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food...
The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration...
The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and...
The FDA approved the RET inhibitor selpercatinib for children with thyroid cancer and other solid tumors harboring various RET...